Hikma Pharmaceutic Company Profile (OTC:HKMPF)

About Hikma Pharmaceutic (OTC:HKMPF)

Hikma Pharmaceutic logo

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTC:HKMPF
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: $6.11 billion
  • Outstanding Shares: 240,959,000
Average Prices:
  • 50 Day Moving Avg: $24.72
  • 200 Day Moving Avg: $23.85
  • 52 Week Range: $20.43 - $35.25
P/E:
  • Trailing P/E Ratio: 38.29
  • Foreward P/E Ratio: 14.08
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.95 billion
  • Price / Sales: 3.13
  • Book Value: $9.94 per share
  • Price / Book: 2.55
Dividend:
  • Dividend Yield: 1.1%
Profitability:
  • EBIDTA: $446 million
Misc:
  • Average Volume: 141 shs.
 

Frequently Asked Questions for Hikma Pharmaceutic (OTC:HKMPF)

What is Hikma Pharmaceutic's stock symbol?

Hikma Pharmaceutic trades on the OTC under the ticker symbol "HKMPF."

Who are some of Hikma Pharmaceutic's key competitors?

How do I buy Hikma Pharmaceutic stock?

Shares of Hikma Pharmaceutic can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hikma Pharmaceutic's stock price today?

One share of Hikma Pharmaceutic stock can currently be purchased for approximately $25.35.


MarketBeat Community Rating for Hikma Pharmaceutic (OTC HKMPF)
Community Ranking:  1.4 out of 5 ()
Outperform Votes:  6 (Vote Outperform)
Underperform Votes:  15 (Vote Underperform)
Total Votes:  21
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceutic and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Hikma Pharmaceutic (OTC:HKMPF) (?)
Ratings Breakdown: 2 Sell Ratings, 1 Hold Rating, 1 Buy Rating
Consensus Rating:Hold (Score: 1.75)
Consensus Price Target: N/A

Analysts' Ratings History for Hikma Pharmaceutic (OTC:HKMPF)
Show:
DateFirmActionRatingPrice TargetDetails
5/19/2017Numis Securities LtdReiterated RatingBuy -> AddView Rating Details
5/17/2017Jefferies Group LLCDowngradeBuy -> UnderperformView Rating Details
3/17/2017HSBC Holdings plcDowngradeHold -> ReduceView Rating Details
11/16/2016Morgan StanleyUpgradeEqual Weight -> OverweightView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Hikma Pharmaceutic (OTC:HKMPF)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Hikma Pharmaceutic (OTC:HKMPF)
Current Year EPS Consensus Estimate: $1.39 EPS
Next Year EPS Consensus Estimate: $1.80 EPS

Dividends

Dividend History for Hikma Pharmaceutic (OTC:HKMPF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Hikma Pharmaceutic (OTC:HKMPF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Hikma Pharmaceutic (OTC:HKMPF)
Latest Headlines for Hikma Pharmaceutic (OTC:HKMPF)
Source:
DateHeadline
finance.yahoo.com logo[$$] Hikma shares hit after cutting sales forecasts
finance.yahoo.com - May 22 at 11:02 AM
americanbankingnews.com logoHikma Pharmaceutic (HKMPF) Earns "Add" Rating from Numis Securities Ltd
www.americanbankingnews.com - May 19 at 10:52 AM
finance.yahoo.com logoHikma Trims Full Year Revenue Guidance After Advair Diskus Delay
finance.yahoo.com - May 19 at 10:12 AM
americanbankingnews.com logoHikma Pharmaceutic to Post FY2017 Earnings of $1.08 Per Share, Jefferies Group Forecasts (HKMPF)
www.americanbankingnews.com - May 19 at 8:20 AM
americanbankingnews.com logoHikma Pharmaceutic (HKMPF) to Post FY2021 Earnings of $1.78 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 18 at 3:52 PM
americanbankingnews.com logoHikma Pharmaceutic (HKMPF) Downgraded to Underperform at Jefferies Group LLC
www.americanbankingnews.com - May 17 at 10:21 AM
finance.yahoo.com logoHuge Downgrades Loom Over Hikma Pharmaceuticals
finance.yahoo.com - May 17 at 10:13 AM
finance.yahoo.com logo[$$] Pets at Home hits record low on profit warning fears
finance.yahoo.com - May 13 at 9:37 AM
finance.yahoo.com logo[$$] SuperGroup's wholesale change translates into sales
finance.yahoo.com - May 13 at 9:37 AM
finance.yahoo.com logoHikma Pharmaceuticals Plc :HKMPF-US: Earnings Analysis: For the six months ended December 31, 2016 : April 12, 2017
finance.yahoo.com - April 12 at 9:22 AM
finance.yahoo.com logoShould You Drop What You're Doing and Buy Jazz Pharmaceuticals Stock?
finance.yahoo.com - April 7 at 5:34 PM
finance.yahoo.com logoMarket Cheers Jazz Pharmaceuticals Patent Settlement
finance.yahoo.com - April 7 at 10:14 AM
finance.yahoo.com logoThis Rival Might Swipe 20% Of Jazz's Sleep Business, But Stock Perks Up
finance.yahoo.com - April 7 at 10:14 AM
finance.yahoo.com logoTime for some game theory: A look at Jazz Pharma’s latest settlement
finance.yahoo.com - April 7 at 10:14 AM
americanbankingnews.com logoHikma Pharmaceutic (HKMPF) Cut to Reduce at HSBC Holdings plc
www.americanbankingnews.com - March 23 at 8:05 AM

Social

This page was last updated on 5/29/2017 by MarketBeat.com Staff